Neubig R R, Gantzos R D, Brasier R S
Mol Pharmacol. 1985 Nov;28(5):475-86.
The agonist- and antagonist-binding properties of the alpha 2-adrenergic receptor in a purified plasma membrane preparation from human platelets were determined both by direct binding of radiolabeled ligands and by competition with the labeled alpha 2-antagonist, [3H] yohimbine. Binding of [3H]yohimbine was characterized by a single high affinity binding site (Kd = 6.2 +/- 1.4 nM, Bmax = 507 +/- 53 fmol/mg). In direct binding studies, the imidazoline full alpha 2-agonist, [3H]-5-bromo-6-N(2-4,5-dihydroimidazolyl)quinoxaline ([3H] UK 14,304), bound to only one quantifiable high affinity site (Kd = 0.88 +/- 0.17 nM), representing 65 +/- 6% of the number of [3H]yohimbine sites. Binding of the partial agonist [3H]-p-aminoclonidine (PAC) showed nonlinear Scatchard plots. Analysis according to a model of multiple independent binding sites showed the data to be consistent with two sites (Kd1 = 0.62 +/- 0.18 nM and Kd2 = 7.9 +/- 1.4 nM). The high affinity site corresponded to 15 +/- 6% and the low affinity site corresponded to 39 +/- 6% of the number of [3H]yohimbine sites. Competition for binding of the alpha 2-antagonist, [3H]yohimbine, with nonradiolabeled ligands revealed a single affinity for yohimbine. In contrast, competition for [3H]yohimbine binding by the full agonist UK 14,304 and epinephrine is best fit by a model with two independent binding sites. The partial agonist PAC was best characterized by a model with three distinct binding sites. The full agonists UK 14,304 and epinephrine inhibited adenylate cyclase approximately 30%, whereas PAC produced only 12% inhibition. The inhibitory guanine nucleotide-binding protein (Ni) with Mr 40,700 was the sole pertussis toxin substrate in the purified membranes. It was quantitated by pertussis toxin-catalyzed [32P]ADP ribosylation in cholate extracts. There is a 20- to 100-fold excess of Ni over alpha 2-adrenergic receptors. Comparisons made between the experimental data for agonist binding and theoretical predictions of the simple ternary complex model suggest that there is compartmentalization of Ni and/or that the alpha 2 receptors are heterogeneous.
通过放射性标记配体的直接结合以及与标记的α2拮抗剂[3H]育亨宾的竞争,测定了来自人血小板的纯化质膜制剂中α2肾上腺素能受体的激动剂和拮抗剂结合特性。[3H]育亨宾的结合以单一高亲和力结合位点为特征(Kd = 6.2±1.4 nM,Bmax = 507±53 fmol/mg)。在直接结合研究中,咪唑啉类完全α2激动剂[3H]-5-溴-6-N(2-4,5-二氢咪唑基)喹喔啉([3H] UK 14,304)仅结合到一个可定量的高亲和力位点(Kd = 0.88±0.17 nM),占[3H]育亨宾位点数量的65±6%。部分激动剂[3H]-对氨基可乐定(PAC)的结合显示出非线性Scatchard图。根据多个独立结合位点模型进行分析表明,数据与两个位点一致(Kd1 = 0.62±0.18 nM和Kd2 = 7.9±1.4 nM)。高亲和力位点占[3H]育亨宾位点数量的15±6%,低亲和力位点占39±6%。α2拮抗剂[3H]育亨宾与非放射性标记配体的结合竞争显示对育亨宾有单一亲和力。相比之下,完全激动剂UK 14,304和肾上腺素对[3H]育亨宾结合的竞争最适合由具有两个独立结合位点的模型来描述。部分激动剂PAC最好由具有三个不同结合位点的模型来表征。完全激动剂UK 14,304和肾上腺素对腺苷酸环化酶的抑制约为30%;而PAC仅产生12%的抑制。分子量为40,700的抑制性鸟嘌呤核苷酸结合蛋白(Ni)是纯化膜中唯一的百日咳毒素底物。通过在胆酸盐提取物中百日咳毒素催化的[32P]ADP核糖基化对其进行定量。Ni比α2肾上腺素能受体过量20至100倍。激动剂结合的实验数据与简单三元复合物模型的理论预测之间的比较表明,存在Ni的区室化和/或α2受体是异质性的。